title: Systemic treatment of acute liver failure with adipose derived stem cells.
abstract: OBJECTIVE
  The definitive treatment for liver failure is, currently, liver transplantation. Research into other possible treatments, focused on achieving regeneration of the liver parenchyma, have led to the development of methods to generate hepatocytes from stem cells. In our study, we transplant allogenic adipose-derived stem cells (ASCs), not previously differentiated to hepatocytes, to treat acute liver failure induced by intraperitoneal administration of carbon tetrachloride (CCl4) in a Sprague-Dawley rat model.
  
  
  METHODS
  The ASCs were delivered via the tail vein, having previously been labeled with PKH26, a fluorescent membrane marker. Two control groups were established, Group 1(n = 15) consisting of olive oil (5 mL/kg) and Group 2(n = 15): 1 × 10(6) PKH26-labeled ASCs. Further, two study groups, Group 3(n = 30): CCl4 dissolved in olive oil and Group 4(n = 30): CCl4 dissolved in olive oil and 1 × 10(6) PKH26-labeled ASCs completed the experimental design.
  
  
  RESULTS
  Blood samples were analyzed, finding AST and ALT levels significantly higher in treatment over control groups at 24 and 48 hours. The mortality rates were statistically different between control groups and Group 3 (Group 1-3 p = .04, Group 2-3 p = .04) and between Groups 3 and 4 (p = .02). Examining the liver parenchyma, a significantly higher number of ASCs were observed in Group 4 than in Group 2 at all time points (p = .00).
  
  
  CONCLUSIONS
  The intravenous injection of allogenic ASCs in this model of CCl4-induced liver failure reduced the mortality in treated animals. ASCs injected in the rat tail vein were found in the liver in animals with induced acute liver failure.
authors.affiliation: 1Hospital Universitario Infanta Sofía, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Pascual-Miguelañez
authors.forename: Javier
authors.initials: J
authors.lastname: Salinas-Gomez
authors.forename: David
authors.initials: D
authors.lastname: Fernandez-Luengas
authors.forename: Karen
authors.initials: K
authors.lastname: Villar-Zarra
authors.forename: Luz Vega
authors.initials: LV
authors.lastname: Clemente
authors.forename: Mariano
authors.initials: M
authors.lastname: Garcia-Arranz
authors.forename: Damian Garcia
authors.initials: DG
authors.lastname: Olmo
mesh_terms: D000273:Adipose Tissue / Q000166:cytology*; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002251:Carbon Tetrachloride / Q000008:administration & dosage / Q000009:adverse effects; D002454:Cell Differentiation / Q000502:physiology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D056486:Chemical and Drug Induced Liver Injury / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D022781:Hepatocytes / Q000166:cytology* / Q000502:physiology; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008099:Liver / Q000502:physiology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D002251:Carbon Tetrachloride; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
keywords: adult stem cells; fulminant liver failure; liver failure; liver transplant; mesenchymal stem cells